The Next Generation of the GLP-1 Revolution Is Already Underway

Executive Summary of Recent Developments

• Latest Update (May 11, 2026): SureNano Science Ltd. released preclinical data for GEP-44, a triple agonist peptide targeting obesity and Type 2 Diabetes. The company claims superior efficacy compared to first-generation GLP-1 therapies like liraglutide.
• Key Metrics: Preclinical studies show approximately 15% body weight reduction (vs ~9% for liraglutide) and food intake reductions approaching 39%.
• Tolerability: Reported avoidance of nausea and gastrointestinal side effects common in first-generation agonists.
• Development Stage: Advancing through IND-enabling studies toward Phase I clinical trials.
• Delivery Platform: Evaluating oral, sublingual, and intranasal delivery to reduce dependence on injectables.
• Strategic Expansion: Early-stage discussions regarding ibogaine-related intellectual property for addiction/mental health formulations.

Evaluation of Most Recent News

• Incremental Progress: The May 11 news confirms progress on the toxicology studies announced in April 2026. It provides specific efficacy data but does not announce a new major milestone like Phase I initiation or regulatory approval.
• Market Expectations: Given the acquisition was finalized in February and study initiation in April, preclinical results are expected milestones within this timeline. The market has already priced in the asset's potential through previous price movements (Jan 2026 peak).
• Price Action Context: Despite positive news flow from Feb to May, the stock price declined significantly from a high of $0.39 (January) to $0.18 (May). This suggests skepticism regarding execution or cash runway rather than lack of pipeline progress.
• Risk Profile: The news is positive for the asset but does not address the immediate capital needs. With ~$1.25M raised in December 2026 and significant quarterly marketing costs (~$100k/year) plus toxicology expenses, cash runway appears limited without further dilution.

Business Model

• Core Business: Transitioning from surfactant technology provider to pharmaceutical developer.
• Flagship Project: GEP-44, a triple agonist peptide (GLP-1, PYY Y1/Y2) for obesity and Type 2 Diabetes.
• Technology Platform: Diversified drug-delivery system targeting oral, sublingual, and intranasal administration to improve patient adherence over injectables.